Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2016 · 10-Q
Revenue$19.52M$19.52M+6.0% vs Q2 2015 Net Income-$6.17M-$6.17MN/M vs Q2 2015 EPS Diluted-$0.30-$0.30N/M vs Q2 2015 Operating Income$3,969,000−9.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$9,588,000−4.4% Margins · derivedOperating margin20.3%−3.4 pt vs Q2 2015
Net margin-31.6%
ended Jun 30, 2016 · filed Aug 4, 2016 · 35 d after period end